Invitation to the Stakeholder Information Session on the Transfer of pCODR to CADTH

April 25, 2014

Hello:

On April 1, 2014, the pan-Canadian Oncology Drug Review (pCODR) was transferred to CADTH to further enhance and consolidate policy direction across the different drug programs, and to improve the pCODR governance structure to ensure its long-term viability and sustainability.

CADTH and pCODR have been working closely together on Phase 1 of this transition to ensure a seamless transfer of pCODR staff, processes, funding, and expertise, so that the pCODR program remains intact under CADTH's governance structure.

As part of our long-standing commitment to stakeholder engagement, CADTH is inviting representatives from pharmaceutical manufacturers, associations and consultants to attend an information/Q&A session on the progress to date and next steps for the pCODR transition.

Monday, June 9, 2014
1:00 p.m. to 2:30 p.m. EDT
The Grand Hotel Toronto
225 Jarvis Street
Toronto, ON
M5B 2C1

The discussion panellists from CADTH will include:

- Dr. Brian O'Rourke, President and Chief Executive Officer, CADTH
- Dr. Anthony (Tony) Fields, Chair, pCODR Expert Review Committee
- Mr. Scott Livingstone, Chair, pCODR Advisory Committee; Chief Executive Officer, Saskatchewan Cancer Agency
- Dr. Mona Sabharwal, Executive Director, pCODR

The purpose of this information session will be:

- To provide stakeholders with a detailed update on Phase 1 of the pCODR transition work.
- To seek input from the pharmaceutical industry on Phase 2 of the transition. Phase 2 is intended to explore better alignment of the pCODR and CADTH Common Drug Review processes and to build upon best practices. Our intent is to use this input to help inform and guide our next steps for this work.

To help us plan for the upcoming session, we will be conducting a short online survey to identify some of the questions and issues that the pharmaceutical industry may have regarding the transition. An online survey will be sent the first week of May.

We value the contributions of pharmaceutical manufacturers, associations, and consultants in supporting the pCODR process, and we hope you will be able to join us for the stakeholder session.

RSVP: Please confirm your attendance at this information session using our online registration form by **June 3, 2014**. As space is limited, each organization will be allowed no more than **3 participants**. Once we have your RSVP, we will send you the agenda.